NanoViricides Inc. (NNVC) is Trading Higher on Unusual Volume for February 12

Equities Staff  |

NanoViricides Inc. (NNVC) experienced unusually high volume on Feb. 12, as the stock gained 9.15% to a closing price of $1.79. The stock saw 241,909 shares trade hands over the course of the day on 493 trades. Given that the stock’s average daily volume over the last month has been 157,759 shares a day, this represents a pretty substantial spike over the norm.

NanoViricides Inc. has a P/B ratio of 3.65. The stock has traded between $3.15 and $0.89 over the last 52-weeks, its 50-day SMA is now $1.20, and its 200-day SMA $1.38.

Nanoviricides Inc is a development stage nano-biopharmaceutical company. Its business activities are to discover, develop and commercialize therapeutics to take care of patients suffering from life-threatening viral infections.

Headquartered in Shelton, CT, NanoViricides Inc. has 6 employees and is currently under the leadership of CEO Eugene Seymour.

For a complete fundamental analysis analysis of NanoViricides Inc., check out’s Stock Valuation Analysis report for NNVC. To see the latest independent stock recommendations from’s analysts, visit our Research section.


The Russell 3000 is not well known outside the world of finance, but it’s one of the strongest indices out there for getting a broad sense of the stock market. Unlike the better-known Dow Jones Industrial Average or S&P 500, membership on the Russell 3000 isn’t selected by committee. It’s simply the 3,000 most valuable companies in the country.

With 3,000 stocks making up the index, it gives a broad look at the markets, including the small-and mid-cap companies that aren’t on the Dow or the S&P 500. And with a rules-based system for determining membership, there’s no bias that could potentially limit membership. That’s why many financial professionals will turn to the Russell 3000 long before the better-known indices when trying to take the temperature of the market.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:



Symbol Last Price Change % Change










World Economic Forum at Davos 2019 - Kitty Parry CEO DeepView

Matt Bird sits down with Kitty Parry, CEO DeepView, at the World Economic Forum at Davos 2019

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.